Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

Viatris

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: Ziprasidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174447

A1281060

Details and patient eligibility

About

Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone

Enrollment: 43 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who successfully completed study A1281031 (CGI score of 1 or 2 at final visit) or ZIP-NY-98035 and with QTc <= 500 msec.

Exclusion criteria

• All other patients who do not fit the inclusion criteria as stated above.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

43 participants in 1 patient group

A1

Experimental group

Treatment:

Drug: Ziprasidone